<DOC>
	<DOCNO>NCT01346930</DOCNO>
	<brief_summary>The MUSIC OL study open-label extension study , eligible patient complete double-blind AC-055B201/MUSIC study schedule receive macitentan 10 mg daily . The study objective ass long-term safety tolerability macitentan patient idiopathic pulmonary fibrosis ( IPF ) .</brief_summary>
	<brief_title>Safety Tolerability Study Macitentan Patients With Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Macitentan</mesh_term>
	<criteria>Signed informed consent prior initiation studyrelated procedure . Patients IPF complete doubleblind AC055B201/MUSIC study schedule , i.e. , remain study sponsordeclared endofstudy ( EOS ) , whether study treatment prematurely discontinue . Women childbearing potential must negative pretreatment serum pregnancy test must use reliable method contraception study treatment least 28 day study treatment termination . Any major violation protocol AC055B201/MUSIC . Premature discontinuation study treatment AC055B201/MUSIC study due adverse event ( AE ) assess relate use macitentan , exclude event IPF worsen . Pregnancy breastfeed . AST and/or ALT &gt; 3 time upper limit normal range . Any known factor disease might interfere treatment compliance , study conduct interpretation result , drug alcohol dependence psychiatric disease . Known hypersensitivity drug class macitentan , excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Idiopathic pulmonary fibrosis</keyword>
	<keyword>IPF</keyword>
	<keyword>pulmonary fibrosis</keyword>
</DOC>